Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
55.92
+0.28 (0.51%)
Jun 10, 2026, 9:54 AM EDT - Market open
Royalty Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,441 | 2,378 | 2,264 | 2,355 | 2,237 | 2,289 | |
Revenue Growth (YoY) | 7.80% | 5.06% | -3.86% | 5.24% | -2.28% | 7.87% |
Cost of Revenue | -366.18 | -295.84 | 732.46 | 560.66 | 904.24 | 452.84 |
Gross Profit | 2,807 | 2,674 | 1,531 | 1,794 | 1,333 | 1,837 |
Selling, General & Admin | 622.27 | 573.48 | 236.67 | 249.75 | 227.3 | 182.83 |
Depreciation & Amortization Expenses | - | - | - | - | 5.67 | 23 |
Research & Development | 441.29 | 452 | 2 | 52 | 177.11 | 200.08 |
Other Operating Expenses | 154.78 | 89.03 | - | - | 615.83 | - |
Total Operating Expenses | 1,218 | 1,115 | 238.67 | 301.75 | 1,026 | 405.91 |
Operating Income | 1,588 | 1,560 | 1,292 | 1,492 | 307.07 | 1,431 |
Interest Income | 21.46 | 33.59 | 47.34 | 72.29 | 78.34 | 53.54 |
Interest Expense | -335.95 | -307.66 | -225.51 | -187.19 | -187.96 | -166.14 |
Other Non-Operating Income (Expense) | 86.16 | -111.15 | -140.5 | -192.03 | 50.57 | -37.93 |
Total Non-Operating Income (Expense) | -228.34 | -385.22 | -318.67 | -306.93 | -59.06 | -150.53 |
Pretax Income | 1,359 | 1,324 | 1,331 | 1,700 | 230.06 | 1,241 |
Net Income | 1,359 | 1,324 | 1,331 | 1,700 | 230.06 | 1,241 |
Minority Interest in Earnings | 531.73 | 553.25 | 471.83 | 565.25 | 187.23 | 621.47 |
Net Income to Common | 827.29 | 770.95 | 858.98 | 1,135 | 42.83 | 619.73 |
Net Income Growth | -24.35% | -10.25% | -24.31% | 2549.49% | -93.09% | -36.44% |
Shares Outstanding (Basic) | 433 | 430 | 448 | 448 | 438 | 415 |
Shares Outstanding (Diluted) | 433 | 564 | 594 | 603 | 438 | 415 |
Shares Change (YoY) | -2.56% | -4.99% | -1.46% | 37.66% | 5.59% | -43.84% |
EPS (Basic) | 1.91 | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 |
EPS (Diluted) | 1.91 | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 |
EPS Growth | -22.36% | -6.81% | -24.51% | 2430.00% | -93.29% | 12.88% |
Free Cash Flow | 2,612 | 2,490 | 2,769 | 2,988 | 2,144 | 2,018 |
Free Cash Flow Growth | 4.91% | -10.08% | -7.32% | 39.36% | 6.27% | -0.84% |
Free Cash Flow Per Share | 6.03 | 4.41 | 4.66 | 4.96 | 4.90 | 4.86 |
Dividends Per Share | 0.895 | 0.880 | 0.840 | 0.800 | 0.760 | 0.680 |
Dividend Growth | 1.70% | 4.76% | 5.00% | 5.26% | 11.77% | 126.67% |
Gross Margin | 115.00% | 112.44% | 67.64% | 76.19% | 59.58% | 80.22% |
Operating Margin | 65.08% | 65.58% | 57.10% | 63.37% | 13.73% | 62.49% |
Profit Margin | 55.69% | 55.68% | 58.79% | 72.20% | 10.28% | 54.21% |
FCF Margin | 107.02% | 104.69% | 122.33% | 126.89% | 95.83% | 88.12% |
EBITDA | 1,590 | 1,563 | 1,292 | 1,492 | 307.07 | 1,431 |
EBITDA Margin | 65.13% | 65.74% | 57.10% | 63.37% | 13.73% | 62.49% |
EBIT | 1,588 | 1,560 | 1,292 | 1,492 | 307.07 | 1,431 |
EBIT Margin | 65.08% | 65.58% | 57.10% | 63.37% | 13.73% | 62.49% |